id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2003-E-0114-0007,FDA,FDA-2003-E-0114,Certificate Extending Patent Term from U.S. Patent and Trademark Office to Novartis,Rule,Certificate Extending Patent Term,2006-09-15T04:00:00Z,2006,9,,,2025-10-31T09:00:07Z,,0,0,0900006480485158
FDA-2003-E-0114-0006,FDA,FDA-2003-E-0114,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2004-10-21T04:00:00Z,2004,10,,,2025-10-30T16:49:08Z,,0,0,0900006480485155
FDA-2003-E-0114-0005,FDA,FDA-2003-E-0114,Determination of Regulatory Review Period for Purposes of Patent Extension; ZELNORM,Notice,General Notice,2004-03-16T05:00:00Z,2004,3,2004-03-15T05:00:00Z,,2025-10-30T16:47:12Z,04-5758,0,0,0900006480485153
FDA-2003-E-0114-0004,FDA,FDA-2003-E-0114,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2004-03-05T05:00:00Z,2004,3,,,2025-10-30T16:36:57Z,,0,0,0900006480485151
FDA-2003-E-0114-0003,FDA,FDA-2003-E-0114,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2004-01-16T05:00:00Z,2004,1,,,2025-10-30T16:34:51Z,,0,0,090000648048514e
FDA-2003-E-0114-0002,FDA,FDA-2003-E-0114,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2003-11-24T05:00:00Z,2003,11,,,2025-10-30T16:30:11Z,,0,0,090000648048514c
FDA-2003-E-0114-0001,FDA,FDA-2003-E-0114,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2003-09-04T04:00:00Z,2003,9,,,2025-10-30T16:28:21Z,,0,0,09000064804850f4